OmniAb (OABI) Net Income towards Common Stockholders Growth (1y) (2022 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -58.11% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -95.76% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -290.15% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 59.59% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -129.68% |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -10.08% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1,228.66% |
| 10 | OmniAb | 334.72 Mn | 291.75 Mn | 14.41 Mn | 57.65% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 57.65% |
| Dec 31, 2025 | -8.50% |
| Sep 30, 2025 | -0.93% |
| Jun 30, 2025 | -16.46% |
| Mar 31, 2025 | 4.01% |
| Dec 31, 2024 | 7.01% |
| Sep 30, 2024 | -4.03% |
| Jun 30, 2024 | 7.45% |
| Mar 31, 2024 | -210.84% |
| Dec 31, 2023 | -306.06% |
| Sep 30, 2023 | -3,090.44% |
| Jun 30, 2023 | -1,032.98% |
| Mar 31, 2023 | -66.26% |
| Dec 31, 2022 | 2,924.40% |
| Sep 30, 2022 | -845.26% |
| Jun 30, 2022 | -59,393.50% |
| Mar 31, 2022 | -47,022.94% |